PRODUCT NEWS

CE-IVD marking of the Respiratory Bacterial ELITe MGB® Panel for the detection of M.pneumoniae, C.pneumoniae and L.pneumophila

Puteaux, France, 12th February 2017 – ELITechGroup Molecular Diagnostics announces today the launch of a high-performance multiplex assay, Respiratory Bacterial ELITe MGB® Panel, for the diagnosis of bacterial respiratory infections, validated with ELITe InGenius®, ELITechGroup’s fully automated sample to result system. Respiratory infections are common causes of morbidity and mortality worldwide. Regardless of the pathogen involved, similar symptoms can be observed making the diagnosis difficult to establish from only considering a symptom-based approach. Using a molecular diagnostic method is crucial to effectively determine the pathogens involved, prevent the misuse of antibiotics, and ensure an optimal patient management. In combination with ELITe InGenius, the Respiratory Bacterial ELITe MGB® Panel is the first panel specifically designed to detect main relevant respiratory bacteria, CE-IVD validated with a sample-to-result system. Respiratory Bacterial ELITe MGB® Panel detects and differentiates in one single reaction M. pneumoniae, C. pneumoniae, and L. pneumophila. The clinical study has demonstrated excellent performance: 100% diagnostic sensitivity and 100% diagnostic specificity were obtained with all targets. The validation with ELITe InGenius offers many advantages to laboratories in comparison to other solutions available on the market: fully automated workflow from extraction to result interpretation, hands-on time reduced to few minutes, and accurate results. “We are proud to extend the ELITe InGenius respiratory menu which now enables laboratories to diagnose the main relevant virus and bacteria involved in respiratory infections. Aligned with our menu expansion strategy, this new assay strengthens the ELITe InGenius offer providing our customers with the largest CEIVD menu for infectious disease testing available on an integrated sample-to-result solution” commented Christoph Gauer, CEO of ELITechGroup. The CE-IVD ELITe InGenius respiratory menu will be further broadened in the coming months with a new Real-Time PCR assay for the detection of Mycobacterium tuberculosis and associated multidrug resistant forms to rifampicin, and isoniazid.

Latest news

NEWSROOM

ELITechGroup Announces Regulatory Approval of its Blood Borne Virus Panel in Japan

ELITechGroup’s blood-borne virus (BBV) panel received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) The ELITe BBV panel was launched in 2022 and comprises three quantitative IVD assays targeting Human Immunodeficiency virus-1 (HIV-1), Human Hepatitis B Virus (HBV), and Human Hepatitis C Virus (HCV) Turin, June 13, 2024: ELITechGroup…

ELITechGroup achieves a new CE-IVDR Certification

ELITechGroup continues to expand its portfolio of IVDR-certified PCR assays to support European diagnostic laboratories The newly obtained IVDR certificate will expedite the transition to IVDR for quantitative Class C infectious diseases assays The company is fully committed to delivering its entire portfolio of nearly 60 molecular assays as IVDR…

ELITechGroup Launches Second IVDR Certified Gastrointestinal Infection Assay: GI Parasitic PLUS ELITe MGB® Kit 

ELITechGroup launches their second kit of the Gastrointestinal infection assay panel targeting parasitic pathogens.  The ELITe MGB Gastrointestinal assays are IVDR-certified in combination with InGenius and BeGenius, fully automated samples-to-results instruments.  The company will shortly launch two more gastrointestinal assay infection panels targeting viral pathogens and Norovirus.   ELITechGroup announces the…

Let us help you

For general inquiries, please use the links to the right. The Contact link leads to a brief online form, and the Support link offers general phone and email information. Someone will be in touch with you soon.